Critical review of non-statin treatments for dyslipoproteinemia

Patients with dyslipoproteinemia, including those with statin intolerance, residual cardiovascular risk, homozygous familial hypercholesterolemia, and lipoprotein lipase deficiency

Non-statin lipid-modifying therapies (fibrates, ezetimibe, bile acid sequestrants, n-3 fatty acids, niacin, mipomersen, lomitapide, gene replacement therapy)